Cas no for 366789-02-8,Rivaroxaban ACID Cas number search msds database,online free cas number chemistry search engine,cas number sigma aldrich - PharmaSources.com

Products
Suppliers
Sourcing Requests

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

Home > CAS No. Inquiry > 366789-02-8

366789-02-8

[CAS Name] Rivaroxaban

[Formula] C19H18ClN3O5S

Search Products Post Sourcing Request

Basica Info

[CAS Name]Rivaroxaban
[Alias]5-Chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide; Rivaroxaban intermediates; 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]oxazolidin-5-yl]methyl]thiophene-2-carboxamide; rivaroxban
[Number]366789-02-8
[EINECS]
[Formula]C19H18ClN3O5S
[Molecular weight]435.8813

[Boiling point]732.609°C at 760 mmHg
[Density]0mmHg at 25°C
[Flash point]396.868°C

366789-02-8 Suppliers

Company

Main Products

Hangzhou Celor Chemical Co.,Ltd.	GMP	Send Inquiry
Jinan Jianfeng Chemical Co., Ltd.	Aliase: Rivaroxaban Purity: 99% Appearance:White or almost white powder Usage: Rivaroxaban is recommended as an option for treating pulmonary embolism and preventing recurrent deep vein thrombosis and pulmonary embolism in adults. Rivaroxaban (Xarelto, Bayer) is indicated for the 'treatment of deep vein thrombosis and pulmonary embolism, and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults'. For the initial treatment of acute pulmonary embolism, the recommended dosage of nivaroxaban is 15 mg twice daily for the first 21 days followed by 20mg once daily for continued treatment and prevention of recurrent venous thromboembolism.Non-Valvular Atrial Fibillation (NVAF)* to prevent stroke & systemic embolism.Acute VTE treatment & prevention of recurrent VTE [for deep vein thrombosis (DVT) and pulmonary embolism (PE)].Prevention of venous thromboembolic events (VTE) in elective total hip or knee replacement surgery (THR, TKR).	Send Inquiry
Sichuan Omnis Pharmaceutical Co., Ltd.	Currently Apixaban is under development, and estimated to market in the end of 2019.	Send Inquiry

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us: About PharmaSources; Terms of Service; Privacy Policy; Event Data Sharing Notice; Intellectual Property; Media Partners

Buy: Search Products; Post Sourcing Requests; Search Suppliers; CAS Search

Sell: Member Application; Advertising; Post Products; EZSourcing

Events: CPHI China; PMEC China; Conferences; Search Events

Help: FAQ; Contact Us; Feedback

Copyright 2006-2025 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved) 沪ICP备05034851号-182 沪公网安备31010402010101号
Links：
CCCMHPIE SJGLE.com JJGLE.COM JDGLE.COM XIUGLE.COM DENGGLE.COM HPGLE.COM
Follow Us：
Pharma Sources Insight January 2025

PharmaSources Customer Service